Imatinib mesylate in the treatment of chronic myelogenous leukemia : Current therapeutic approach for chronic myeloid/Myeloproliferative disorder: Focus on imatinib mesylateBORTHAKUR, Gautam; CORTES, Jorge E.International journal of hematology. 2004, Vol 79, Num 5, pp 411-419, issn 0925-5710, 9 p.Article

Chronic myeloid leukemia : Diagnosis and treatmentQUINTAS-CARDAMA, Alfonso; CORTES, Jorge E.Mayo Clinic proceedings. 2006, Vol 81, Num 7, pp 973-988, issn 0025-6196, 16 p.Article

Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous LeukemiaGANDHI, Varsha; PLUNKETT, William; CORTES, Jorge E et al.Clinical cancer research (Print). 2014, Vol 20, Num 7, pp 1735-1740, issn 1078-0432, 6 p.Article

Molecular Monitoring in Chronic Myeloid Leukemia : Response to Tyrosine Kinase Inhibitors and Prognostic ImplicationsJABBOUR, Elias; CORTES, Jorge E; KANTARJIAN, Hagop M et al.Cancer. 2008, Vol 112, Num 10, pp 2112-2118, issn 0008-543X, 7 p.Article

First-line therapy for chronic myeloid leukemia : past, present, and futurePAVLOVSKY, Carolina; KANTARJIAN, Hagop; CORTES, Jorge E et al.American journal of hematology. 2009, Vol 84, Num 5, pp 287-293, issn 0361-8609, 7 p.Article

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia : What Is the Optimal Strategy?JABBOUR, Elias; CORTES, Jorge E; KANTARJIAN, Hagop M et al.Mayo Clinic proceedings. 2009, Vol 84, Num 2, pp 161-169, issn 0025-6196, 9 p.Article

Biology of platelet-derived growth factor and its involvement in diseaseALVAREZ, Ricardo H; KANTARJIAN, Hagop M; CORTES, Jorge E et al.Mayo Clinic proceedings. 2006, Vol 81, Num 9, pp 1241-1257, issn 0025-6196, 17 p.Article

The role of Src in solid and hematologic malignancies : Development of new-generation Src inhibitorsALVAREZ, Ricardo H; KANTARJIAN, Hagop M; CORTES, Jorge E et al.Cancer. 2006, Vol 107, Num 8, pp 1918-1929, issn 0008-543X, 12 p.Article

Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicinYUK FUNG HUI; CORTES, Jorge E.Pharmacotherapy. 2000, Vol 20, Num 10, pp 1221-1223, issn 0277-0008Conference Paper

Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: Recall following different chemotherapy agentsYUK FUNG HUI; GILES, Francis J; CORTES, Jorge E et al.Investigational new drugs. 2002, Vol 20, Num 1, pp 49-53, issn 0167-6997, 5 p.Article

Early Cytogenetic and Molecular Response During First-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase: Long-Term ImplicationsQUINTAS-CARDAMA, Alfonso; CORTES, Jorgé E; KANTARJIAN, Hagop M et al.Cancer. 2011, Vol 117, Num 23, pp 5261-5270, issn 0008-543X, 10 p.Article

Dasatinib Treatment for Philadelphia Chromosome-positive Leukemias : Practical ConsiderationsKHOURY, Hanna Jean; GUILHOT, Francois; HUGHES, Timothy P et al.Cancer. 2009, Vol 115, Num 7, pp 1381-1394, issn 0008-543X, 14 p.Article

Current and emerging treatment options in chronic myeloid leukemiaJABBOUR, Elias; CORTES, Jorge E; GILES, Francis J et al.Cancer. 2007, Vol 109, Num 11, pp 2171-2181, issn 0008-543X, 11 p.Article

Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemiaCHEN, Lisa S; REDKAR, Sanjeev; TAVERNA, Pietro et al.Blood. 2011, Vol 118, Num 3, pp 693-702, issn 0006-4971, 10 p.Article

Practical Advice for Determining the Role of BCR-ABL Mutations in Guiding Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid LeukemiaJABBOUR, Elias; BRANFORD, Susan; SAGLIO, Giuseppe et al.Cancer. 2011, Vol 117, Num 9, pp 1800-1811, issn 0008-543X, 12 p.Article

Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML TherapyKANTARJIAN, Hagop M; BACCARANI, Michele; JABBOUR, Elias et al.Clinical cancer research (Print). 2011, Vol 17, Num 7, pp 1674-1683, issn 1078-0432, 10 p.Article

Farnesyltransferase inhibitors: Novel compounds in development for the treatment of myeloid malignanciesCORTES, Jorge E; KURZROCK, Razelle; KANTARJIAN, Hagop M et al.Seminars in hematology. 2002, Vol 39, Num 3, pp 26-30, issn 0037-1963, SUP2Article

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) studyBACCARANI, Michele; DRUKER, Brian J; HUGHES, Timothy P et al.International journal of hematology. 2014, Vol 99, Num 5, pp 616-624, issn 0925-5710, 9 p.Article

Impact of Numerical Variation in FMS-Like Tyrosine Kinase Receptor 3 Internal Tandem Duplications on Clinical Outcome in Normal Karyotype Acute Myelogenous LeukemiaBORTHAKUR, Gautam; KANTARJIAN, Hagop; PATEL, Keyur P et al.Cancer. 2012, Vol 118, Num 23, pp 5819-5822, issn 0008-543X, 4 p.Article

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsMÜLLER, Martin C; CORTES, Jorge E; MUKHOPADHYAY, Jaydip et al.Blood. 2009, Vol 114, Num 24, pp 4944-4953, issn 0006-4971, 10 p.Article

Kinase Domain Point Mutations in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Emerge After Therapy With BCR-ABL Kinase InhibitorsJONES, Dan; THOMAS, Deborah; YIN, C. Cameron et al.Cancer. 2008, Vol 113, Num 5, pp 985-994, issn 0008-543X, 10 p.Article

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemiaGILES, Francis J; TALLMAN, Martin S; KANTARJIAN, Hagop M et al.Cancer. 2004, Vol 100, Num 7, pp 1449-1458, issn 0008-543X, 10 p.Article

The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phaseSNEED, Thomas B; KANTARJIAN, Hagop M; GILES, Francis et al.Cancer. 2004, Vol 100, Num 1, pp 116-121, issn 0008-543X, 6 p.Article

Investigational strategies in chronic myelogenous leukemiaCORTES, Jorge E; O'BRIEN, Susan M; GILES, Francis et al.Hematology/oncology clinics of North America. 2004, Vol 18, Num 3, issn 0889-8588, ix, 619-639 [22 p.]Article

Phase I and pharmacodynamic study of Triapine®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemiaGILES, Francis J; FRACASSO, Paula M; WRIGHT, Lisa P et al.Leukemia research. 2003, Vol 27, Num 12, pp 1077-1083, issn 0145-2126, 7 p.Article